Joel Linden

31.1k total citations · 8 hit papers
324 papers, 25.7k citations indexed

About

Joel Linden is a scholar working on Physiology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Joel Linden has authored 324 papers receiving a total of 25.7k indexed citations (citations by other indexed papers that have themselves been cited), including 225 papers in Physiology, 124 papers in Molecular Biology and 53 papers in Cellular and Molecular Neuroscience. Recurrent topics in Joel Linden's work include Adenosine and Purinergic Signaling (225 papers), Receptor Mechanisms and Signaling (81 papers) and Neuropeptides and Animal Physiology (36 papers). Joel Linden is often cited by papers focused on Adenosine and Purinergic Signaling (225 papers), Receptor Mechanisms and Signaling (81 papers) and Neuropeptides and Animal Physiology (36 papers). Joel Linden collaborates with scholars based in United States, Australia and Germany. Joel Linden's co-authors include Kenneth A. Jacobson, Adriaan P. IJzerman, Bertil B. Fredholm, Caglar Cekic, Karl‐Norbert Klotz, Yuan‐Ji Day, Jayson Rieger, Mark D. Okusa, Gail W. Sullivan and Luiz Belardinelli and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Joel Linden

322 papers receiving 25.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors

2001 2.2k citations Joel Linden et al. profile →
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

2007 1.8k citations Silvia Deaglio, Joel Linden et al. profile →
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update

2011 1.1k citations Joel Linden et al. profile →
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

2008 961 citations Joel Linden et al. profile →
The cardiac effects of adenosine

1989 624 citations Joel Linden et al. profile →
Purinergic regulation of the immune system

2016 616 citations Caglar Cekic, Joel Linden profile →
Molecular Approach to Adenosine Receptors: Receptor-Mediated Mechanisms of Tissue Protection

2001 556 citations Joel Linden profile →
Purine Release, Metabolism, and Signaling in the Inflammatory Response

2019 276 citations Joel Linden et al. profile →

Peers

Countries citing papers authored by Joel Linden

Since Specialization

Citations

This map shows the geographic impact of Joel Linden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Linden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Linden more than expected).

Fields of papers citing papers by Joel Linden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Linden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Linden. The network helps show where Joel Linden may publish in the future.

Co-authorship network of co-authors of Joel Linden

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Linden. A scholar is included among the top collaborators of Joel Linden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Linden. Joel Linden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Improved survival of SARS COV-2-infected K18-hACE2 mice treated with adenosine A2AR agonist 2023 ·Heliyon ·Barbara J. Mann, Preeti Chhabra, (unknown), (unknown), Riley T. Hannan, Jeffrey M. Sturek, (unknown), Joel Linden, Kenneth L. Brayman	3
2	Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors 2021 ·Cancer Research ·Lin Wang, Luz M. Londono, (unknown), Özge Saatci, (unknown), Pelin G. Ersan, Sara Serra, Hong Pei, (unknown), Qiping Zhao, Kim B. Phan, Lei Huang, Michael J. LaBarre, Xiaoming Li, H. Michael Shepard, Silvia Deaglio, Joel Linden, Christopher D. Thanos, Özgür Şahin, Caglar Cekic	29
3	The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8+ T-cell Responses and Promotes Tumor Growth 2020 ·Cancer Immunology Research ·Siqi Chen, (unknown), Jie Fan, Joel Linden, Bin Zhang, Caglar Cekic	56
4	Cellular sensing of extracellular purine nucleosides triggers an innate IFN-β response 2020 ·Science Advances ·Rekha Dhanwani, Mariko Takahashi, Ian T. Mathews, (unknown), (unknown), Jeramie D. Watrous, Bartijn C. H. Pieters, Catherine C. Hedrick, Chris A. Benedict, Joel Linden, Roland Nilsson, Mohit Jain, Sonia Sharma	25
5	Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease 2019 ·PLoS ONE ·Jonathan R. Lindner, Todd Belcik, Michael E. Widlansky, Leanne Harmann, Matthew S. Karafin, Nancy J. Wandersee, Mäneka Puligandla, Donna Neuberg, Joel Linden, Joshua J. Field	7
6	A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment 2017 ·Cancer Research ·Arabella Young, Shin Foong Ngiow, (unknown), Ann‐Marie Patch, Deborah S. Barkauskas, Meriem Messaoudene, Gene Lin, Jérôme D. Coudert, Kimberley Stannard, Laurence Zitvogel, Mariapia A. Degli‐Esposti, Éric Vivier, Nicola Waddell, Joel Linden, Nicholas D. Huntington, Fernando Souza-Fonseca-Guimarães, Mark J. Smyth	296
7	Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment 2014 ·Cancer Research ·Caglar Cekic, Joel Linden	142
8	Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment 2014 ·Cancer Research ·Caglar Cekic, Yuan‐Ji Day, Duygu Sağ, Joel Linden	240
9	Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson 2013 ·Blood ·Joshua J. Field, Gene Lin, Maureen Okam, Elaine M. Majerus, Jeffrey R. Keefer, Onyinye Onyekwere, (unknown), Federico Campigotto, Donna Neuberg, Joel Linden, David G. Nathan	72
10	Adenosine A2B receptor signaling in antigen presenting cells suppress anti-tumor adaptive immune responses (127.10) 2012 ·The Journal of Immunology ·Caglar Cekic, Joel Linden	1
11	Regulation of Lymphocyte Function by Adenosine 2012 ·Arteriosclerosis Thrombosis and Vascular Biology ·Joel Linden, Caglar Cekic	123
12	P-Selectin–Mediated Platelet-Neutrophil Aggregate Formation Activates Neutrophils in Mouse and Human Sickle Cell Disease 2010 ·Arteriosclerosis Thrombosis and Vascular Biology ·Renata Polanowska‐Grabowska, Kori Wallace, Joshua J. Field, (unknown), Melissa A. Marshall, Robert A. Figler, Adrian R.L. Gear, Joel Linden	148
13	Adenosine A2A Receptor Signaling and Golf Assembly Show a Specific Requirement for the γ7 Subtype in the Striatum 2010 ·Journal of Biological Chemistry ·William F. Schwindinger, (unknown), (unknown), Kelly S. Betz, (unknown), Joel Linden, Denis Hervé, Janet D. Robishaw	47
14	The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells 2009 ·The Journal of Immunology ·Jeffrey M. Wilson, William G. Ross, Oma N. Agbai, (unknown), Robert A. Figler, Jayson Rieger, Joel Linden, Peter B. Ernst	113
15	Abstract 1423: The Cardioprotective Effects of Postconditioning Against Acute Myocardial Infarction are Mediated by Adenosine A2A Receptor Activation 2006 ·Circulation ·Zequan Yang, Yaqin Xu, Amy Lankford, Joel Linden, Jakob Vinten‐Johansen, Brent A. French	5
16	Renal Ischemia-Reperfusion Injury and Adenosine 2A Receptor-Mediated Tissue Protection: The Role of CD4+ T Cells and IFN-γ 2006 ·The Journal of Immunology ·Yuan‐Ji Day, Liping Huang, Hong Ye, Li L, Joel Linden, Mark D. Okusa	179
17	Cutting Edge: Critical Role for A2A Adenosine Receptors in the T Cell-Mediated Regulation of Colitis 2006 ·The Journal of Immunology ·Makoto Naganuma, (unknown), Courtney M. Lappas, Joel Linden, Mark Worthington, Peter B. Ernst	200
18	A2A Adenosine Receptor Induction Inhibits IFN-γ Production in Murine CD4+ T Cells 2005 ·The Journal of Immunology ·Courtney M. Lappas, Jayson Rieger, Joel Linden	320
19	A2A Adenosine Receptors on Bone Marrow-Derived Cells Protect Liver from Ischemia-Reperfusion Injury 2005 ·The Journal of Immunology ·Yuan‐Ji Day, Yuesheng Li, Jayson Rieger, Susan I. Ramos, Mark D. Okusa, Joel Linden	84
20	Building a Better Fluid for Emergency Resuscitation of Traumatic Brain Injury 2004 ·The Journal of Trauma: Injury, Infection, and Critical Care ·Bruce Crookes, Stephen M. Cohn, (unknown), Elizabeth A. Burton, (unknown), Matthias Majetschak, Albert J. Varon, Joel Linden, Kenneth G. Proctor	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact